Pharmacogenomics Testing Market - Strategic Insights and Forecasts (2026-2031)

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

1. 2.1. Market Overview

2. 2.2. Market Definition

3. 2.3. Scope of the Study

4. 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

1. 3.1. Market Drivers

2. 3.2. Market Restraints

3. 3.3. Market Opportunities

4. 3.4. Porter’s Five Forces Analysis

5. 3.5. Industry Value Chain Analysis

6. 3.6. Policies and Regulations

7. 3.7. Strategic Recommendations

8. 3.8. Product Pipeline Analysis

9. 3.9. Incidence and Prevalence Analysis

10. 3.10. Patent Analysis

4. TECHNOLOGICAL OUTLOOK

5. PHARMACOGENOMICS TESTING MARKET BY PRODUCT TYPE

1. 5.1. Introduction

2. 5.2 Instruments

3. 5.3. Reagents & Kits

4. 5.4. Software & Services

6. PHARMACOGENOMICS TESTING MARKET BY TECHNOLOGY

1. 6.1. Introduction

2. 6.2. Polymerase Chain Reaction (PCR)

3. 6.3. Next-Generation Sequencing (NGS)

4. 6.4. Microarray

5. 6.5. Mass Spectrometry

7. PHARMACOGENOMICS TESTING MARKET BY APPLICATION

1. 7.1. Introduction

2. 7.2. Oncology

3. 7.3. Neurological Disorders

4. 7.4. Autoimmune Diseases

5. 7.5. Metabolic Disorders

6. 7.6. Cardiovascular Diseases

8. PHARMACOGENOMICS TESTING MARKET BY GEOGRAPHY

1. 8.1. Introduction

2. 8.2. North America

   1. 8.2.1. USA

   2. 8.2.2. Canada

   3. 8.2.3. Mexico

3. 8.3. South America

   1. 8.3.1. Brazil

   2. 8.3.2. Argentina

   3. 8.3.3. Others

4. 8.4. Europe

   1. 8.4.1. United Kingdom

   2. 8.4.2. Germany

   3. 8.4.3. France

   4. 8.4.4. Spain

   5. 8.4.5. Others

5. 8.5. Middle East and Africa

   1. 8.5.1. Saudi Arabia

   2. 8.5.2. UAE

   3. 8.5.3. Others

6. 8.6. Asia Pacific

   1. 8.6.1. China

   2. 8.6.2. India

   3. 8.6.3. Japan

   4. 8.6.4. South Korea

   5. 8.6.5. Indonesia

   6. 8.6.6. Thailand

   7. 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

1. 9.1. Major Players and Strategy Analysis

2. 9.2. Market Share Analysis

3. 9.3. Mergers, Acquisitions, Agreements, and Collaborations

4. 9.4. Competitive Dashboard

10. COMPANY PROFILES

1. 10.1. Roche Diagnostics

2. 10.2. Thermo Fisher Scientific

3. 10.3. QIAGEN

4. 10.4. Illumina

5. 10.5. Abbott Laboratories

6. 10.6. Agilent Technologies

7. 10.7. Danaher Corporation

8. 10.8. Myriad Genetics

9. 10.9. Invitae

10. 10.10 Bio-Rad Laboratories

11. APPENDIX

1. 11.1. Currency

2. 11.2. Assumptions

3. 11.3. Base and Forecast Years Timeline

4. 11.4. Key benefits for the stakeholders

5. 11.5. Research Methodology

6. 11.6. Abbreviations